A recent large-scale study has unveiled a concerning link between the weight-loss drug Wegovy and a significantly increased risk of sudden vision loss, particularly when compared to its diabetes counterpart, Ozempic. The findings, published in the British Journal of Ophthalmology, suggest that those taking Wegovy may encounter nearly five times the risk of developing non-arteritic anterior ischemic optic neuropathy (Naion), a condition that can lead to permanent vision loss.
Understanding the Risks of Semaglutide
Both Wegovy and Ozempic belong to a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are designed to aid in managing blood sugar levels, reduce appetite, and promote weight loss. However, the new research highlights a crucial distinction between the two drugs. While both contain the active ingredient semaglutide, their different formulations and dosages may play a significant role in the associated health risks.
The study, which analyzed adverse event reports submitted to the US Food and Drug Administration (FDA) from December 2017 to December 2024, found that men on Wegovy were particularly vulnerable, facing a threefold increase in risk compared to women. Researchers noted that “eye strokes,” or Naion, occur due to impaired blood flow to the optic nerve, leading to sudden vision impairment.
The Mechanism Behind Naion
Dr Edward Margolin, a key researcher from the University of Toronto, suggested that Naion is likely a genuine side effect of semaglutide. The rapid weight loss associated with Wegovy, particularly at higher doses, could exacerbate the risk of this condition. The study also indicated that while Naion is infrequent—affecting roughly one in 10,000 users—this potential dose-dependent risk raises concerns for those considering or currently using Wegovy for weight management.
In contrast, the study found no significant association between Rybelsus, another semaglutide formulation taken orally, and Naion, possibly due to the slower absorption rate of the tablet compared to the injectable forms. This difference in pharmacokinetics may elucidate why the injectable Wegovy presents a greater risk.
Regulatory Responses and Ongoing Safety Monitoring
Following the study’s publication, the UK Medicines and Healthcare products Regulatory Agency (MHRA) issued a safety alert regarding Naion risks associated with semaglutide. Dr Alison Cave, the chief safety officer at the MHRA, emphasized the importance of awareness among patients and healthcare providers about potential side effects, despite the overall low incidence of these complications.
Samantha Mann, a consultant ophthalmologist at the Royal College of Ophthalmologists, cautioned against drawing definitive conclusions solely from reported side effects. She noted that while the study indicates a heightened risk, this phenomenon has not been extensively observed in everyday clinical practice at her facility, suggesting that further research is essential to validate these findings.
Novo Nordisk, the manufacturer of Wegovy, Ozempic, and Rybelsus, reassured patients that safety remains their utmost priority. They stated that they continuously collaborate with global regulatory authorities to monitor the safety of their medications. Although updates to patient leaflets for all three drugs now include information about Naion, Novo Nordisk maintains that the overall benefit-risk profile for semaglutide remains favourable.
Why it Matters
The implications of this study are significant, particularly for individuals considering Wegovy as a weight-loss solution. With rising obesity rates and the increasing popularity of GLP-1 RA medications, it is crucial for patients and healthcare professionals to remain vigilant regarding potential side effects. This research underscores the necessity of careful monitoring and open dialogue about the risks associated with these treatments. As more data emerges, it may reshape prescribing practices and patient education, ensuring safer approaches to weight management and diabetes care.
